Status:
COMPLETED
An Inpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Treatment Of Acute Exacerbation Of Schizophrenia
Lead Sponsor:
Pfizer
Conditions:
Schizophrenia
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
This study aims to evaluate whether PF-02545920 is safe and effective in the treatment of acute exacerbation of schizophrenia during a 4-week inpatient treatment period. The study will use the Positiv...
Eligibility Criteria
Inclusion
- Diagnosis of schizophrenia with acute exacerbation of illness
- The current acute exacerbation of schizophrenia must be less than 4 weeks duration prior to the initial evaluation.
Exclusion
- Subjects with evidence or history of clinically significant uncontrolled medical illness
- Subjects with a current diagnosis of schizoaffective disorder, major depression, bipolar disorder, or obsessive compulsive disorder.
- Subjects who meet Diagnostic and Statistical Manual-IV (DSM-IV)defined diagnostic criteria for psychoactive substance dependence (excluding nicotine dependence) within 12 months of screening or DSM-IV defined substance abuse within 3 months prior to screening.
Key Trial Info
Start Date :
October 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2011
Estimated Enrollment :
259 Patients enrolled
Trial Details
Trial ID
NCT01175135
Start Date
October 1 2010
End Date
August 1 2011
Last Update
May 22 2018
Active Locations (46)
Enter a location and click search to find clinical trials sorted by distance.
1
K & S Professional Research Services, LLC
Little Rock, Arkansas, United States, 72201
2
Leisure Court Center
Anaheim, California, United States, 92801
3
Early Phase Investigational Center
Escondido, California, United States, 92025
4
Synergy Clinical Research Center of Escondido
Escondido, California, United States, 92025